Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate
Megan J. Shram(Altrecht GGZ), Andrew C. Barrett(KemPharm (United States)), Rene A. Braeckman(KemPharm (United States)), Jarosław Kański(KemPharm (United States)), Bradley Vince(Altasciences Clinical Research Vince & Associates), Debra Kelsh(Altasciences Clinical Research Vince & Associates), Beatrice Setnik, Sven Guenther(KemPharm (United States)), Travis Mickle(KemPharm (United States)), Andrea E. Martin(Max Planck Institute for Psycholinguistics), Lynn R. Webster(Adherent Technologies (United States))
Cited by 11
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304